Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942416 | 0.83 | KMT2A (0.36) | CXCR3ALDH1A1GAAALOX12SMN1; SMN2 | |
| SCHEMBL20942002 | 0.82 | CXCR3 (0.35) | CXCR3ALDH1A1GAAALOX12SMN1; SMN2 | |
| SCHEMBL20941961 | 0.82 | CXCR3 (0.35) | CXCR3ALDH1A1GAAALOX12SMN1; SMN2 | |
| SCHEMBL20942592 | 0.81 | CXCR3 (0.32) | CXCR3 | |
| SCHEMBL20942072 | 0.80 | PTPN11 (0.34) | CXCR3ALDH1A1KCNH2CDK8CDK19 | |
| SCHEMBL11360845 | 0.80 | CXCR3 (0.40) | CXCR3ALDH1A1GAAALOX12SMN1; SMN2 | |
| SCHEMBL20941980 | 0.79 | CXCR3 (0.34) | CXCR3 | |
| SCHEMBL20942077 | 0.79 | CXCR3 (0.34) | CXCR3ALDH1A1CHRM4CHRM1CHRM5 | |
| SCHEMBL20942456 | 0.79 | KMT2A (0.34) | CXCR3ALDH1A1KCNH2CDK8CDK19 | |
| SCHEMBL17101418 | 0.79 | CHRM1 (0.41) | CHRM4CHRM1KCNH2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ALLERGAN, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | CXCR3 721/4885ALDH1A1 3481/4885GAA 3955/4885 |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ENY2, PNMT, CHRM1 | CXCR3 721/4885ALDH1A1 3481/4885GAA 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.